Cargando…

Case Report: An Adolescent Soft Tissue Sarcoma With YWHAE-NUTM2B Fusion Is Effectively Treated With Combined Therapy of Epirubicin and Anlotinib

Soft tissue sarcoma is a relatively rare entity that comprises heterogeneous types of tumors. Here we report the case of a 14-year-old girl with pelvic sarcoma with a YWHAE-NUTM2B fusion gene. This fusion transcript has been reported in endometrial stromal sarcomas and clear cell renal sarcomas, but...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Jiajia, Xu, Yanjie, Ni, Xuefeng, Zhang, Dachuan, Zhao, Jiemin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262382/ https://www.ncbi.nlm.nih.gov/pubmed/35814390 http://dx.doi.org/10.3389/fonc.2022.905994

Ejemplares similares

Neonatal Soft Tissue Sarcoma with YWHAE-NUTM2B Fusion
por: Guizard, Maylis, et al.
Publicado: (2019)

Case of NUTM::CIC fusion sarcoma surrounding inflatable penile prosthesis
por: Mason, J. Bradley, et al.
Publicado: (2023)

High-grade endometrial stromal sarcoma with YWHAE-NUTM2B fusion gene abnormality identified after 10 years of recurrent pulmonary metastases: A case report
por: Takahashi, Yuko, et al.
Publicado: (2023)

YWHAE-NUTM2 oncoprotein regulates proliferation and cyclin D1 via RAF/MAPK and Hippo pathways
por: Ou, Wen-Bin, et al.
Publicado: (2021)

Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma
por: Li, Shenglong
Publicado: (2021)

CNS tumors with YWHAE:NUTM2 and KDM2B-fusions present molecular similarities to extra-CNS tumors having BCOR internal tandem duplication or alternative fusions
por: Tauziède-Espariat, Arnault, et al.
Publicado: (2021)

Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma
por: Wang, Zhi‐Ming, et al.
Publicado: (2020)

RARE-38. CLINICAL PRESENTATION OF MGA-NUTM1 FUSION TRANSCRIPT SARCOMA
por: Pongphitcha, Pongpak, et al.
Publicado: (2020)

Gemcitabine Plus Anlotinib Is Effective and Safe Compared to Gemcitabine Plus Docetaxel in Advanced Soft Tissue Sarcoma
por: Liu, Zhiyong, et al.
Publicado: (2022)

The expanding universe of NUTM1 fusions in pediatric cancer
por: Charlab, Rosane, et al.
Publicado: (2023)

Brain tumor with an ATXN1-NUTM1 fusion gene expands the histologic spectrum of NUTM1-rearranged neoplasia
por: Siegfried, Aurore, et al.
Publicado: (2019)

NTRK3 Overexpression in Undifferentiated Sarcomas with YWHAE and BCOR Genetic Alterations
por: Kao, Yu-Chien, et al.
Publicado: (2020)

Case report: NUT carcinoma with MXI1::NUTM1 fusion characterized by abdominopelvic lesions and ovarian masses in a middle-aged female
por: Jiang, Huahua, et al.
Publicado: (2023)

Erratum: Case report: NUT carcinoma with MXI1::NUTM1 fusion characterized by abdominopelvic lesions and ovarian masses in a middle-aged female
Publicado: (2023)

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas
por: Liu, Zhiyong, et al.
Publicado: (2021)

Undifferentiated Round Cell Sarcoma with BCOR Internal Tandem Duplications (ITD) or YWHAE fusions: A Clinicopathologic and Molecular Study
por: Antonescu, Cristina R, et al.
Publicado: (2020)

Novel MXD4–NUTM1 fusion transcript identified in primary ovarian undifferentiated small round cell sarcoma
por: Tamura, Ryo, et al.
Publicado: (2018)

Efficacy and Safety of Treating Refractory Bone and Soft Tissue Sarcoma with Anlotinib in Different Treatment Patterns
por: Cai, Meng, et al.
Publicado: (2022)

A recurrent novel MGA–NUTM1 fusion identifies a new subtype of high-grade spindle cell sarcoma
por: Diolaiti, Daniel, et al.
Publicado: (2018)

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
por: Wang, Hai-ying, et al.
Publicado: (2020)

Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group
por: Nielsen, Ole S., et al.
Publicado: (2000)

YAP1-NUTM1 Gene Fusion in Porocarcinoma of the External Auditory Canal
por: Agaimy, Abbas, et al.
Publicado: (2020)

Effectiveness and Tolerability of Anlotinib Plus PD-1 Inhibitors for Patients with Previously Treated Metastatic Soft-Tissue Sarcoma
por: Sun, Xin, et al.
Publicado: (2022)

Malignant mediastinal mesothelioma treated with anlotinib: a case report and review of the literature
por: Zhang, Yishi, et al.
Publicado: (2023)

High-Grade Transformation of Low-Grade Endometrial Stromal Sarcomas Lacking YWHAE and BCOR Genetic Abnormalities
por: Zou, Youran, et al.
Publicado: (2020)

Evaluation of Anlotinib Combined with Adriamycin and Ifosfamide as Conversion Therapy for Unresectable Soft Tissue Sarcomas
por: Long, Zuoyao, et al.
Publicado: (2023)

Novel ATXN1/ATXN1L::NUTM2A fusions identified in aggressive infant sarcomas with gene expression and methylation patterns similar to CIC-rearranged sarcoma
por: Xu, Feng, et al.
Publicado: (2022)

RNA-Binding Protein COL14A1, TNS1, NUSAP1 and YWHAE Are Valid Biomarkers to Predict Peritoneal Metastasis in Gastric Cancer
por: Jiang, Yue, et al.
Publicado: (2022)

Novel Nutrition-Based Nomograms to Assess the Outcomes of Lung Cancer Patients Treated With Anlotinib or Apatinib
por: Zheng, Hui, et al.
Publicado: (2021)

A Phase II Study of Docetaxel and Epirubicin in Advanced Adult Soft Tissue Sarcomas (STS)
por: Kalofonos, Haralabos P., et al.
Publicado: (2004)

New therapeutics for soft tissue sarcomas: Overview of current immunotherapy and future directions of soft tissue sarcomas
por: Seong, Gyuhee, et al.
Publicado: (2023)

Efficacy and safety of anlotinib plus camrelizumab in treating retroperitoneal soft tissue sarcomas: a single-center retrospective cohort study
por: Wu, Jianhui, et al.
Publicado: (2023)

Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Nanomaterial Technology and Soft Tissue Sarcomas
por: Zhou, Changkai, et al.
Publicado: (2022)

Pembrolizumab Plus Chemotherapy or Anlotinib vs. Pembrolizumab Alone in Patients With Previously Treated EGFR-Mutant NSCLC
por: Chen, Ya, et al.
Publicado: (2021)

Thyroid Carcinoma with NSD3::NUTM1 Fusion: a Case with Thyrocyte Differentiation and Colloid Production
por: Allison, Derek B., et al.
Publicado: (2022)

Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab
por: Liu, Zhujun, et al.
Publicado: (2022)

The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: A retrospective analysis
por: Shen, Fangcheng, et al.
Publicado: (2023)

Risk-stratified patients with resectable soft tissue sarcoma benefit from epirubicin-based adjuvant chemotherapy
por: Schenone, Aaron D, et al.
Publicado: (2014)

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group.
por: Nielsen, O. S., et al.
Publicado: (1998)

Cannot write session to /tmp/vufind_sessions/sess_01qorpral1a4uuil734c10ursr